<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="49439">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02462603</url>
  </required_header>
  <id_info>
    <org_study_id>EPI589-15-002</org_study_id>
    <nct_id>NCT02462603</nct_id>
  </id_info>
  <brief_title>Safety and Biomarker Study of EPI-589 in Parkinson's Disease</brief_title>
  <official_title>A Phase 2A Safety and Biomarker Study of EPI-589 in Mitochondrial Subtype and Idiopathic Parkinson's Disease Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edison Pharmaceuticals Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edison Pharmaceuticals Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label study with 30-day run-in phase and adaptive design component to include more
      subjects if deemed appropriate by investigators.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a within-subject, controlled open-label study seeking to determine if EPI-589 can
      alter the biochemical signature of PD as assessed by peripheral blood and brain imaging
      biomarkers. Data will also be collected on disease-relevant clinical measures will be
      collected.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as assessed by drug related AEs</measure>
    <time_frame>3 months</time_frame>
    <description>Safety as assessed by drug related adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarker assessments as measured in cerebrospinal fluid, blood and urine</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Disease State as assessed by the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS)</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease morbidity as assessed by composites scales including Non-motor Symptoms Scale (NMSS), PDQ-39 and EQ-5D</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function as assessed by composite scales including MoCA and DRS-2 scales</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood as assessed by composite scales including the BDI and MADRS scales</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate changes in pharmacokinetics parameters (cmax) for all treated subjects pre and 3 months post treatment with EPI-589</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as evidenced by development of drug related adverse events after treament with EPI-589</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>EPI-589 500 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All enrolled subjects will receive treatment with EPI-589</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPI-589</intervention_name>
    <description>EPI-589 is a redox active molecule and will be provided in a 250 mg tablet formulation.</description>
    <arm_group_label>EPI-589 500 mg bid</arm_group_label>
    <other_name>(R)-Troloxamide quinone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hoehn and Yahr stage ≤ 2.5

          -  Ambulatory with or without assistance

          -  Agreement to use contraception if within reproductive years

          -  Willingness and ability to comply with study procedures

          -  Stable regimen of dietary supplements for 30 days prior to enrollment

          -  Abstention from use of other investigative or nonapproved drugs for the duration of
             the trial

        For Idiopathic Subjects

          -  A diagnosis of early idiopathic PD confirmed by the presence of bradykinesia plus one
             or both of the following symptoms: rigidity or resting tremor; and with an abnormal
             DaTscan consistent with a dopaminergic deficit

          -  Must not yet require symptomatic medications for PD and not expected to require such
             treatment before the end of the study

          -  Age 40 to 75 years

          -  Within 5 years of diagnosis of Parkinson's disease

        For Genetic Subtype Subjects

          -  A confirmed diagnosis of PD plus a genetic diagnosis consistent with PD, specifically
             PINK1, parkin, LARK2 or other genetic subtype

          -  Age 21 to 75 years

          -  Stable medication regimen of PD drugs for 30 days (except 60 days for rasagiline)
             prior to enrollment

        Exclusion Criteria:

          -  Allergy to EPI-589 or other components of the EPI-589 tablet formulation

          -  Use of antioxidant supplements, specifically vitamins E and C beyond the recommended
             daily allowance

          -  Other Parkinsonian disorders

          -  MoCA score of &lt;24

          -  Revised Hamilton Rating Scale for Depression ≥ 11

          -  Parkinsonism due to drugs or toxins

          -  Diagnosis of any other clinically significant neurologic disease that will confound
             the assessment of effect of study drug on disease progression

          -  Malignancy within past two years

          -  Pregnant or plans to become pregnant or breast feeding

          -  History of stroke

          -  History of brain surgery

          -  Hepatic insufficiency with liver function tests (LFTs) &gt;3 times upper limit of normal

          -  Renal insufficiency as defined by creatinine &gt; 1.5 times normal

          -  End stage cardiac failure

          -  Participation within past 3 months and for duration of study in a trial of a device,
             drug or other therapy for PD

        For Idiopathic Subjects

          -  Use of any MAO inhibitors, amantadine or other drugs prescribed for core symptoms of
             Parkinson's disease for idiopathic subjects

          -  Use of nortriptyline or fluvoxamine 60 days prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew B Klein, MD FACS</last_name>
    <role>Study Director</role>
    <affiliation>Edison Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew B Klein, MD, FACS</last_name>
    <phone>650-641-9211</phone>
    <email>mklein@edisonpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erin P Johnson, BA</last_name>
    <phone>650-641-9212</phone>
    <email>ejohnson@edisonpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David K Simon, MD, PhD</last_name>
      <phone>617-735-3251</phone>
      <email>dsimon1@bidmc.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Althea Silver, MPH, BSN, RN</last_name>
      <phone>617-667-9885</phone>
      <email>asilver2@bidmc.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David K Simon, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College of London,Dept. of Clinical Neuroscience</name>
      <address>
        <city>London</city>
        <zip>NW3 2PF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huw Morris, PhD, FRCP</last_name>
      <phone>020 7794 0500</phone>
      <phone_ext>36833</phone_ext>
      <email>h.morris@ucl.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Vincenzo Libri, MD,PhD, FRCP</last_name>
      <phone>+44 (0) 20 3448 4538</phone>
      <phone_ext>4101</phone_ext>
      <email>vincenzo.libri@ucl.ac.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 12, 2016</lastchanged_date>
  <firstreceived_date>May 20, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's Disease</keyword>
  <keyword>PD</keyword>
  <keyword>EPI-589</keyword>
  <keyword>EPI589</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
